BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 17
• 18
• 19
• 20
• 21
• 22
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Biotech Bay

  CancerVX, an OncoEpigenetic DNA Immuno Therapy From World Cancer Institute Targets Female Hormonal Cancers, 5 Other Solid Tumor and 4 Hematological Malignancies and May Become the First Bioactive Personalized Universal Cancer Vaccine

  World Cancer Institute Inc., today announced the evolutionary platform of cancer clinical protocols originating initially in 2008 /2009 based on molecular cancer genetics and DNA programmable pharmaceutics to inhibit the growth, replication and proliferation of human cancer cells.

  December 21, 2017

   · 

  2 min read
• 

  Business

  Histogenics, MEDINET Ink Pact for Development and Commercialization of NeoCart for the Japanese Market

  Transaction Terms Include a $10M Up-front Payment with a Potential of $87m in Total Milestones, and Tiered Royalties on Sales

  December 21, 2017

   · 

  9 min read
• Pharm Country

  FDA Updates SYMBICORT Label With LABA Safety Class Revisions and Removes Boxed WARNING for Serious Asthma-Related Outcomes

  AstraZeneca today announced FDA has approved updates to the SYMBICORT (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol labeling, including removal of the Boxed WARNING for serious asthma-related outcomes.

  December 21, 2017

   · 

  9 min read